European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the Company’s type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. “Given the need for new treatment options for patients with multiple myeloma, we look forward to working closely with the EMA as they review this application,” said Fouad Namouni, M.D., head, oncology development, Bristol-Myers Squibb. “It is our hope that this new Empliciti-based combin
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers, Cellares ink $380M CAR-T therapies supply deal [Seeking Alpha]Seeking Alpha
- Interstitial Lung Disease Pipeline Research 2024: Therapeutic Assessment of 120+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/2/24 - Beat
BMY
Sec Filings
- 4/22/24 - Form DEFA14A
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- BMY's page on the SEC website